Harry Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Richard L. Cassin Editor at Large

Elizabeth K. Spahn Editor Emeritus 

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

« Kozeny Wins In Privy Council | Main | Let Press Freedom Ring »

China Province Hits Medical Graft

From the China Compliance Digest (Issue No. 8: March 26, 2012):

Officials in the southern province of Yunnan announced the approval of regulatory changes designed to stem medical corruption, including the introduction of a blacklist of bribery offenders.
Facilities, companies, and personnel implicated in corruption will be ineligible for official commendations. In addition, doctors involved in serious corruption cases may have their medical licenses revoked.
Pharmaceutical companies involved in serious corruption cases will be barred from submitting products to the health department for approval.
Source: Health Paper (健康报)


For a limited time, subscribers to the FCPA Blog will receive a complimentary one-month subscription to the China Compliance Digest. Subscribe to the FCPA Blog by filling in the box on the left under 'Connect.'

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
All HTML will be escaped. Hyperlinks will be created for URLs automatically.